Thorsten Stuhmer

Wuerzburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma.

VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma.

Journal: Scientific reports
Published: October 23, 2025

Efficacy of melflufen in multiple myeloma with mutated or deleted TP53.

Efficacy of melflufen in multiple myeloma with mutated or deleted TP53.

Journal: Experimental hematology & oncology
Published: August 11, 2025

Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma.

Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma.

Journal: Blood cancer journal
Published: June 11, 2024

Functional Investigation of IGF1R Mutations in Multiple Myeloma.

Functional Investigation of IGF1R Mutations in Multiple Myeloma.

Journal: Cancers
Published: April 24, 2024

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.

Journal: HemaSphere
Published: November 19, 2023

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma.

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma.

Journal: Blood cancer journal
Published: November 07, 2022

Cereblon enhancer methylation and IMiD resistance in multiple myeloma.

Cereblon enhancer methylation and IMiD resistance in multiple myeloma.

Journal: Blood
Published: December 17, 2020

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma.

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma.

Journal: Blood cancer journal
Published: September 03, 2020

Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models.

Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models.

Journal: Scientific reports
Published: April 23, 2020

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.

Journal: Cancers
Published: November 29, 2019

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.

Journal: Haematologica
Published: October 10, 2019

IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma.

IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma.

Journal: Haematologica
Published: September 28, 2019
Showing 1-12 of 39

Last Updated: 09/26/2026